|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12...3435363738394041424344...4950» |
- valacyclovir / Generic mfg.
Trial withdrawal: An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Washington
Recruiting --> Withdrawn
- valacyclovir / Generic mfg.
Enrollment change: An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Washington
Recruiting --> Withdrawn N=20 --> 0
- ||||| Intelence (etravirine) / J&J
New P4 trial: A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence (clinicaltrials.gov) - Dec 3, 2012
P4, N=3000, Active, not recruiting, Sponsor: Janssen Korea, Ltd., Korea
- ||||| Prezista (darunavir) / J&J
New P4 trial: A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista (clinicaltrials.gov) - Dec 3, 2012
P4, N=3000, Recruiting, Sponsor: Janssen Korea, Ltd., Korea
- Trial completion: TL01: Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine (clinicaltrials.gov) - Dec 3, 2012
P1, N=8, Completed, Sponsor: St George's, University of London
N=20 --> 0 Active, not recruiting --> Completed
- zidovudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P2 trial, Combination therapy: A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects (clinicaltrials.gov) - Nov 28, 2012
P2, N=0, Withdrawn, Sponsor: RFS Pharma, LLC
- lopinavir/ritonavir / Generic mfg.
Trial completion: Comparison of Liquid Kaletra and Low Dose Kaletra Tablets (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=8, Completed, Sponsor: Phoenix Children's Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | tenofovir disoproxil fumarate / Generic mfg., zidovudine / Generic mfg.
New P2a trial, Combination therapy: A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects. (clinicaltrials.gov) - Nov 27, 2012
P2a, N=45, Active, not recruiting, Sponsor: RFS Pharma, LLC
- Dapivirine Vaginal Ring (dapivirine) / International Partnership for Microbicides, J&J
Trial completion: Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring (clinicaltrials.gov) - Nov 26, 2012
P1, N=48, Completed, Sponsor: International Partnership for Microbicides, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || New P3 trial: An Evaluation of a Rapid Test for HIV (clinicaltrials.gov) - Nov 25, 2012
P3, N=497, Completed, Sponsor: Pontificia Universidad Catolica de Chile
- Enrollment change: Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer (clinicaltrials.gov) - Nov 20, 2012
P2, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=30 --> 10
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Adherence: Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens (clinicaltrials.gov) - Nov 19, 2012
P=N/A, N=51, Completed, Sponsor: University of California, San Francisco
N=30 --> 10 Active, not recruiting --> Completed
- artemether/lumefantrine / Generic mfg.
New P4 trial: Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy (clinicaltrials.gov) - Nov 18, 2012
P4, N=48, Recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Enrollment closed: Feasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected Women (clinicaltrials.gov) - Nov 18, 2012
P=N/A, N=100, Active, not recruiting, Sponsor: Duke University
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- | efavirenz / Generic mfg., abacavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed: NEVEREST-III: Treatment Options for Protease Inhibitor-exposed Children (clinicaltrials.gov) - Nov 17, 2012
P3, N=400, Active, not recruiting, Sponsor: Columbia University
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial termination: Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV (clinicaltrials.gov) - Nov 15, 2012
P2, N=130, Terminated, Sponsor: AIDS Clinical Trials Group
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; The DSMB concluded that the findings regarding the primary analysis would persist and that no additional study goals would be achieved by continuing the study.
- |||| Intelence (etravirine) / J&J
Trial completion: INROADS: A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients (clinicaltrials.gov) - Nov 15, 2012
P2, N=54, Completed, Sponsor: Tibotec, Inc
Active, not recruiting --> Terminated; The DSMB concluded that the findings regarding the primary analysis would persist and that no additional study goals would be achieved by continuing the study. Active, not recruiting --> Completed
- | Trial completion: A Study of Anti-HIV Monoclonal Antibody KD-247 (clinicaltrials.gov) - Nov 15, 2012
P1, N=27, Completed, Sponsor: The Chemo-Sero-Therapeutic Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population (clinicaltrials.gov) - Nov 13, 2012
P=N/A, N=150, Recruiting, Sponsor: University of Buenos Aires
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P4 trial: A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients (clinicaltrials.gov) - Nov 12, 2012
P4, N=0, Withdrawn, Sponsor: Janssen Pharmaceutica
- | Enrollment change: Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults (clinicaltrials.gov) - Nov 11, 2012
P2, N=26, Completed, Sponsor: Aeras
Not yet recruiting --> Recruiting N=900 --> 26
- | Trial completion: Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults (clinicaltrials.gov) - Nov 11, 2012
P2, N=26, Completed, Sponsor: Aeras
N=900 --> 26 Recruiting --> Completed
- | Prezista (darunavir) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment change: Clinical Trial of CNS-targeted HAART (CIT2) (clinicaltrials.gov) - Nov 8, 2012
P2/3, N=59, Completed, Sponsor: University of California, San Diego
Recruiting --> Completed N=120 --> 59
- | Prezista (darunavir) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
Trial completion: Clinical Trial of CNS-targeted HAART (CIT2) (clinicaltrials.gov) - Nov 8, 2012
P2/3, N=59, Completed, Sponsor: University of California, San Diego
N=120 --> 59 Recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, IO biomarker: VIKING-4: Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir (clinicaltrials.gov) - Nov 7, 2012
P3, N=30, Active, not recruiting, Sponsor: ViiV Healthcare
Recruiting --> Completed Recruiting --> Active, not recruiting
- | PENNVAX-B (HIV clade B DNA vaccine) / Inovio
Trial completion: HIV-001: Study of PENNVAX (clinicaltrials.gov) - Nov 7, 2012
P1, N=12, Completed, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Clinical: VICAR2: Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women (clinicaltrials.gov) - Nov 6, 2012
P=N/A, N=166, Recruiting, Sponsor: University of Witwatersrand, South Africa
- Isentress (raltegravir) / Merck (MSD)
Trial completion, Combination therapy: Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis (clinicaltrials.gov) - Nov 6, 2012
P2, N=155, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil (clinicaltrials.gov) - Nov 5, 2012
P=N/A, N=487, Completed, Sponsor: Cynthia S Firnhaber
Active, not recruiting --> Completed Not yet recruiting --> Completed
- Trial completion: Attitudes and Beliefs and the Steps of HIV Care (clinicaltrials.gov) - Nov 5, 2012
P=N/A, N=200, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial initiation date: Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients (clinicaltrials.gov) - Nov 1, 2012
P=N/A, N=42, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Initiation date: Nov 1999 --> May 2004
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P2/3 trial: Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents (clinicaltrials.gov) - Nov 1, 2012
P2/3, N=50, Recruiting, Sponsor: Gilead Sciences
- Trial completion, Metastases: Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs (clinicaltrials.gov) - Oct 31, 2012
P=N/A, N=100, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Nov 1999 --> May 2004 Active, not recruiting --> Completed
- Trial completion: A Comparison of Two Anti-HIV Treatment Plans (clinicaltrials.gov) - Oct 31, 2012
P=N/A, N=480, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: The Biology of HIV Transmission (clinicaltrials.gov) - Oct 31, 2012
P=N/A, N=20, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: A Study to Monitor Patients With Primary or Early HIV Infection (clinicaltrials.gov) - Oct 31, 2012
P=N/A, N=1500, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- Selzentry (maraviroc) / ViiV Healthcare
New P1 trial: First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers (clinicaltrials.gov) - Oct 30, 2012
P1, N=21, Recruiting, Sponsor: Fundacio Lluita Contra la SIDA
- didanosine / Generic mfg., zidovudine / Generic mfg.
Trial completion: A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection (clinicaltrials.gov) - Oct 30, 2012
P1, N=85, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Victrelis (boceprevir) / Roche, Merck (MSD)
New P3 trial: BOC-HIV: HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (clinicaltrials.gov) - Oct 29, 2012
P3, N=128, Not yet recruiting, Sponsor: Anna Cruceta
- Trial completion: HIV and Cardiovascular Risk (clinicaltrials.gov) - Oct 29, 2012
P=N/A, N=129, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Prevalence of Hepatitis C Virus Infection in HIV-Infected Children (clinicaltrials.gov) - Oct 29, 2012
P=N/A, N=600, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
New P2 trial, Combination therapy: A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) (clinicaltrials.gov) - Oct 28, 2012
P2, N=30, Completed, Sponsor: Merck Sharp & Dohme Corp.
- Trial completion: HIV Prevention Preparedness Study in Russia, China, and India (clinicaltrials.gov) - Oct 28, 2012
P=N/A, N=2000, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal: Anti-HIV Medications and Structured Treatment Interruptions for People Recently Infected With HIV (clinicaltrials.gov) - Oct 25, 2012
P=N/A, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Trial termination: Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya (clinicaltrials.gov) - Oct 25, 2012
P3, N=141, Terminated, Sponsor: University of Washington
Not yet recruiting --> Withdrawn Recruiting --> Terminated; DSMB recommended termination because TI was safe but not durable.
- Trial initiation date: Evaluating Host and Viral Factors Among HIV Infected Former Commercial Blood Donors in Fuyang, Anhui Province, China (clinicaltrials.gov) - Oct 25, 2012
P=N/A, N=186, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Terminated; DSMB recommended termination because TI was safe but not durable. Initiation date: Apr 2005 --> Sep 2005
- tenofovir disoproxil fumarate / Generic mfg.
Enrollment change: Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy (clinicaltrials.gov) - Oct 25, 2012
P=N/A, N=17, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Apr 2005 --> Sep 2005 N=56 --> 17
- lopinavir/ritonavir / Generic mfg.
Enrollment change: Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women (clinicaltrials.gov) - Oct 25, 2012
P=N/A, N=116, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=56 --> 17 N=78 --> 116
- Enrollment change: Long-term Follow-up of HIV Infected Patients Identified During Early Infection (clinicaltrials.gov) - Oct 25, 2012
P=N/A, N=157, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=78 --> 116 N=2200 --> 157
- Enrollment change: Voluntary HIV Counseling, Testing, and Medication for Pregnant Women to Prevent Mother-to-Child HIV Transmission (clinicaltrials.gov) - Oct 25, 2012
P=N/A, N=283, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=2200 --> 157 N=400 --> 283